How does the MSD Liver Injury Panel compare to the MILLIPLEX 5-Plex?

The MILLIPLEX Liver Injury 5-Plex includes ARG1, GST-α, SDH, 5'-NT, and GOT1/MDH1 — covering biliary (5'-NT) and additional hepatocellular (SDH) markers beyond our 2-plex. The MSD Liver Injury Panel focuses on the core FDA-recognized hepatocellular markers (ARG1 + GST-α) on the same ECL platform as our kidney and cardiac panels — enabling integrated multi-organ toxicity assessment without switching platforms. The choice depends on whether your priority is maximum liver biomarker coverage (MILLIPLEX) or integrated multi-organ safety on a single platform (MSD ECL).

Home
Platform
MSD Multiplex Assay Services
MSD Liver Injury & Hepatotoxicity Biomarker Panel Services

MSD V-PLEX · MULTI-SPOT

Hepatotoxicity · Drug Safety · DILI

MSD Drug-Induced Liver Injury (DILI) Panel — ARG1 & GST-α Assay

Detect drug-induced liver injury before ALT/AST elevation — using MSD panels measuring Arginase-1 and α-Glutathione S-Transferase (GST-α), two PSTC/FDA-recognized hepatotoxicity biomarkers that provide earlier, liver-specific detection of hepatocellular damage than traditional transaminases.

Arginase-1 is liver-specific — elevated only when hepatocytes are damaged, unlike ALT/AST which can rise from muscle injury. GST-α is released hours before transaminases due to its small size and cytoplasmic location. In PSTC-validated models, both showed up to 250-fold elevation at 24 hours post-hepatotoxicant. MSD's MULTI-SPOT Liver Injury Panel measures both simultaneously from 25 µL — on the same platform as our kidney and cardiac panels for integrated multi-organ safety assessment.

Inquire About Liver Panels View Panel Configurations

Beyond ALT/AST — Liver-Specific Hepatotoxicity Biomarkers

ALT and AST have served as standard liver function markers for decades — but both have fundamental limitations in drug safety assessment. ALT is predominantly hepatic but also expressed in kidney and skeletal muscle. AST is widely distributed across liver, heart, skeletal muscle, kidney, brain, and red blood cells — an elevated AST alone cannot distinguish liver from muscle or cardiac injury. Both rise only after significant hepatocellular damage and can remain elevated for days after the initial insult — providing a delayed, non-specific signal. The PSTC (Predictive Safety Testing Consortium), in collaboration with the FDA and EMA, recognized Arginase-1 and GST-α as liver-specific biomarkers that provide earlier, more specific detection of hepatocellular injury. Arginase-1 is a urea cycle enzyme expressed almost exclusively in hepatocytes; its appearance in circulation directly reflects hepatocyte damage, not muscle or cardiac injury. GST-α is a small cytoplasmic detoxification enzyme released rapidly into circulation upon hepatocellular membrane damage — often hours before ALT/AST elevation in preclinical models.

 Liver Injury Biomarkers — Mechanisms & Advantages
Arginase-1 (ARG1): liver-specific urea cycle enzyme expressed in periportal and perivenous hepatocytes. PSTC/FDA-recognized for preclinical hepatotoxicity. Released exclusively from damaged hepatocytes — unlike ALT/AST, elevation unambiguously indicates liver injury. Measured in the Rat Liver Injury Panel.
α-Glutathione S-Transferase (GST-α): detoxification enzyme highly expressed in hepatocyte cytoplasm. Small molecular size (50 kDa) enables rapid release into circulation upon membrane damage — often hours before ALT/AST. PSTC/FDA-recognized. Provides earlier detection than transaminases in published preclinical models.
Liver specificity vs. ALT/AST: ALT can be elevated from muscle injury; AST is ubiquitous. Arginase-1 is liver-exclusive — when combined with GST-α in a single multiplex measurement, the combination provides both liver specificity (ARG1) and early detection (GST-α) that ALT/AST cannot match.
250-fold dynamic range: published PSTC model data demonstrated up to 250-fold elevation of ARG1 and GST-α at 24 hours post-hepatotoxicant, with return to baseline over 4 days — providing quantitative, temporal injury data for dose-response and time-course analysis.

Liver Injury Panel Configurations

Panel	Plex	Biomarkers	Species	Regulatory Context
Rat Liver Injury Panel (MULTI-SPOT)	2	Arginase-1, GST-α	Rat	PSTC/FDA-recognized biomarkers
Human Liver Injury Markers	2	Arginase-1, GST-α	Human	Available via U-PLEX configuration

The MSD MULTI-SPOT Liver Injury Panel is the MSD-platform version of these hepatotoxicity biomarkers. Additional liver injury markers may be available via U-PLEX or R-PLEX custom development. All services are for research use only.

Electrochemiluminescence for Hepatotoxicity Detection

Advantages for Hepatotoxicity Detection

Liver-specific detection — no muscle cross-reactivity: Arginase-1 is expressed almost exclusively in hepatocytes. Unlike ALT/AST, elevated ARG1 unambiguously indicates liver injury — critical in preclinical studies where muscle damage from restraint, injection, or myotoxic compounds can confound transaminase interpretation.
Earlier detection than ALT/AST: GST-α's small size and cytoplasmic localization enable rapid release upon membrane damage — in published PSTC models, GST-α elevation preceded ALT elevation by hours. Combined with ARG1, the panel provides both early detection and liver specificity.
Same platform as kidney and cardiac panels: liver, kidney (KIM-1, NGAL, Clusterin), and cardiac (troponins, FABP3) injury panels all run on the same MSD instrument — enabling comprehensive multi-organ toxicity assessment without platform switching.
25 µL per panel — serial monitoring: liver, kidney, and cardiac safety panels from 75 µL total plasma per timepoint. Support within-animal longitudinal toxicity assessment rather than terminal-only group comparisons.

Liver Injury Assay Specifications

TechnologyMSD MULTI-SPOT

AnalytesArginase-1, GST-α

Sample Volume25 µL EDTA plasma

Dynamic Range~250-fold (PSTC model data)

Recommended MatrixEDTA Plasma

SpeciesRat, Human

Regulatory ContextPSTC/FDA-recognized biomarkers

PlatformSame as kidney/cardiac panels

ARG1/GST-α vs ALT/AST

Biomarker performance in preclinical hepatotoxicity

Liver Specificity ARG1+GST

Early Detection GST-α

Dynamic Range ARG1+GST

Muscle Confound Risk ALT/AST

Multi-Organ Platform MSD

ARG1 = liver-exclusive; GST-α = earliest release. ALT/AST remain useful but lack specificity. For research use only.

Liver Injury Panel Service Details

Service Package

Item	Full Service	Notes
Sample Processing	Included	EDTA plasma processing protocol
Standard Curves	Per-analyte calibrators	Recombinant ARG1 + GST-α standards
QC Samples	Multi-level, duplicate	Low, medium, high
Data Report	With temporal plots	Serial sampling visualization

For Research Use Only. Not for diagnostic procedures.

How to Get Started

Select Panel

Choose rat or human Liver Injury Panel. Combine with kidney + cardiac panels for multi-organ safety from the same plasma samples.

Collect & Ship

EDTA plasma, processed within 1 hour at 4°C. Serial pre-dose + on-treatment timepoints. Ship on dry ice.

Receive Hepatotoxicity Data

Receive ARG1 + GST-α data with temporal plots, liver-specific injury confirmation, and QC documentation.

Liver Injury Detection: MSD vs ALT/AST vs Alternative Multiplex

Feature	MSD MULTI-SPOT (ARG1 + GST-α)	ALT/AST	Alternative Multiplex 5-Plex
Liver Specificity	High — ARG1 is liver-exclusive	Low — AST ubiquitous, ALT also in muscle/kidney	High — ARG1 + SDH liver-specific
Early Detection	Yes — GST-α released hours before ALT	No — delayed rise, sustained elevation	Yes
Plex Level	2 analytes	2 separate clinical chemistry tests	5 analytes
Platform Integration	Same platform as kidney + cardiac panels	Clinical chemistry analyzer	Separate platform
PSTC/FDA Recognition	Yes — ARG1 + GST-α	Traditional — not PSTC-qualified	Yes — ARG1, GSTα, SDH, 5'-NT

Your Hepatotoxicity Data Package

Hepatotoxicity biomarker data — ARG1 and GST-α concentrations with per-analyte QC acceptance metrics for each timepoint (Excel + PDF)
ARG1 and GST-α per-well signal data — 4PL standard curves, and plate layout maps for each analytical run
Injury kinetics plots — fold-change vs. pre-dose baseline across all timepoints, showing hepatocellular injury onset, peak magnitude, and recovery trajectory
Liver-specific injury verification — ARG1 elevation (liver-exclusive) documented alongside GST-α timing to differentiate true hepatocellular damage from potential muscle confound affecting transaminases
Methods documentation — complete panel composition, calibrator lot information, and QC protocol for regulatory documentation or publication

Advantages of ARG1/GST-α Over Traditional Transaminases

Liver-specific — no muscle or cardiac confound: Arginase-1 is expressed almost exclusively in hepatocytes. When ARG1 is elevated, the injury is hepatic — eliminating the diagnostic ambiguity of elevated AST or ALT in preclinical studies with potential muscle involvement
Same platform as kidney + cardiac panels: liver, kidney, and cardiac safety from 75 µL total plasma — comprehensive multi-organ toxicity assessment without platform switching, reagent incompatibility, or cross-platform variability
PSTC/FDA-recognized biomarkers: Arginase-1 and GST-α are recognized by the PSTC consortium for preclinical hepatotoxicity — providing regulatory-context-appropriate biomarker data for IND-enabling studies
Earlier than ALT/AST: GST-α's rapid release kinetics detect hepatocellular damage before transaminase elevation — enabling earlier intervention decisions in preclinical safety studies
Serial monitoring from 25 µL: within-animal longitudinal hepatotoxicity data rather than terminal-only group comparisons — temporal resolution of injury onset, peak, and recovery

Liver Injury & Hepatotoxicity Panel FAQ

Why use Arginase-1 and GST-α instead of ALT and AST?

ALT and AST have two fundamental limitations in drug safety: lack of liver specificity (AST is ubiquitous in muscle, heart, kidney, and RBCs; ALT is also in muscle and kidney) and delayed elevation (rise only after significant hepatocellular damage). Arginase-1 is expressed almost exclusively in hepatocytes — elevated ARG1 unambiguously confirms liver injury, not muscle or cardiac damage. GST-α is rapidly released upon hepatocellular membrane damage due to its small size and cytoplasmic localization — often hours before ALT/AST elevation. In preclinical studies where muscle damage from restraint, injection, or myotoxic compounds can elevate AST and ALT independently of liver injury, ARG1 provides the liver-specific signal that transaminases cannot. For research use only.

How does the MSD Liver Injury Panel compare to broader liver injury multiplex panels?

Broader liver injury multiplex panels on other platforms include additional markers beyond ARG1 and GST-α — such as SDH (sorbitol dehydrogenase, another hepatocellular marker), 5'-NT (5'-nucleotidase, a biliary injury marker), and MDH1 (malate dehydrogenase 1). The MSD Liver Injury Panel focuses on the core FDA-recognized hepatocellular markers (ARG1 + GST-α) on the same platform as our kidney and cardiac panels — enabling integrated multi-organ toxicity assessment without switching platforms. The choice depends on whether your priority is maximum liver biomarker coverage or integrated multi-organ safety on a single MSD platform. For research use only.

Can liver, kidney, and cardiac panels be run from the same preclinical sample?

Yes — all three organ-specific panels require 25 µL each on the same MSD platform. A single 75 µL EDTA plasma aliquot supports comprehensive liver + kidney + cardiac safety assessment at each timepoint in a preclinical repeat-dose toxicology study. This enables within-animal longitudinal multi-organ toxicity profiling — tracking the temporal relationship between hepatotoxicity, nephrotoxicity, and cardiotoxicity from the same sample — rather than running separate assays on different platforms that introduce cross-platform variability. For research use only.

Inquiry Basket